NCT05524545View on ClinicalTrials.gov

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 2, 2022

Primary Completion Date

June 27, 2025

Study Completion Date

June 27, 2025

Conditions
Bladder CancerUrothelial Carcinoma
Interventions
DRUG

Evorpacept

Fusion protein that blocks CD47-SIRPalpha pathway

DRUG

Enfortumab Vedotin

Nectin-4 directed antibody and microtubule inhibitor conjugate

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center, New York

27599

University of North Carolina, Chapel Hill

33612

Moffitt Cancer Center, Tampa

38138

West Clinic, Germantown

75390

UT Southwestern, Dallas

97239

Oregon Health & Science University, Portland

98109

Seattle Cancer Care Alliance, Seattle

02114

Massachusett's General, Boston

Sponsors

Lead Sponsor

ALX Oncology Inc.
All Listed Sponsors
lead

ALX Oncology Inc.

INDUSTRY

NCT05524545 - A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07) | Biotech Hunter | Biotech Hunter